Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 14/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | HPGDS | O60760 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25243118 | 1.00 | NLRP3 (0.51) | NLRP3KCNH2CHRNA7KMT2ATHRB | |
| SCHEMBL23950189 | 0.89 | NLRP3 (0.51) | NLRP3KCNH2CHRNA7KMT2ATHRB | |
| SCHEMBL25753005 | 0.88 | NLRP3 (0.51) | NLRP3KCNH2CHRNA7KMT2ATHRB | |
| SCHEMBL25751754 | 0.87 | NLRP3 (0.50) | NLRP3KCNH2CHRNA7KMT2ATHRB | |
| SCHEMBL30149314 | 0.86 | NLRP3 (0.49) | NLRP3KCNH2CHRNA7KMT2A | |
| SCHEMBL23950454 | 0.85 | NLRP3 (0.48) | NLRP3KCNH2CHRNA7 | |
| SCHEMBL23950511 | 0.79 | NLRP3 (0.62) | NLRP3KCNH2THRBHPGDS | |
| SCHEMBL23950603 | 0.77 | NLRP3 (0.66) | NLRP3KCNH2THRB | |
| SCHEMBL23950990 | 0.75 | NLRP3 (0.67) | NLRP3KCNH2THRB | |
| SCHEMBL23950598 | 0.74 | NLRP3 (0.63) | NLRP3KCNH2THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203044-A1 | PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| US-20230203044-A1 | PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| WO-2021209552-A1 | PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY | JANSSEN PHARMACEUTICA NV (BE) | 2021-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203044-A1 | PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME | NLRP3, PYCARD, NLRP1 | NLRP3 1/4885KCNH2 2596/4885CHRNA7 4228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.